Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 5, 1999, Pages 969-977

  Van Hage Hamsten, Marianne ^a   Kronqvist, Marianne ^a,b   Zetterström, Olle ^a   Johansson, Eva ^a   Niederberger, Verena ^d   Vrtala, Susanne ^d   Grönlund, Hans ^c   Grönneberg, Reidar ^a   Valenta, Rudolf ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c PFIZER INC   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bet v 1; Hypoallergenic Bet v 1 derivatives; Intradermal testing; Recombinant birch pollen allergens; Skin prick testing

Indexed keywords

ADULT; ALLERGENICITY; ANTIGENIC VARIATION; ARTICLE; CLINICAL ARTICLE; FEMALE; GENETIC ENGINEERING; HUMAN; MALE; POLLEN; POLLEN ALLERGY; PREVALENCE; PRICK TEST; PRIORITY JOURNAL; SEASONAL VARIATION; SWEDEN;

EID: 0032739068     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70077-1     Document Type: Article

References (36)

1. 1. Valenta R, Niederberger V, Fischer S, Jäger S, Spitzauer S, Kraft D. Tree pollen allergens. In: Lockey RF, Bukantz SC, editors. Allergen immunotherapy. 2nd ed. New York: Marcel Dekker; 1998. p 85-102.
2. 2. Valenta R, Kraft D. Type I allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. J Allergy Clin lmmunol 1996;97:893-5.
3. 3. World Health Organization/International Union of Immunological Societies Allergen Nomenclature Subcommittee, King TP, Hoffman D, Løwenstein H, Marsh DG, Platts-Mills TAE, et al. Allergen nomenclature. J Allergy Clin Immunol 1995;96:5-14.
4. 4. Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H, et al. The gene coding for the major birch pollen allergen, Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J 1989;8:1935-8.
5. 5. Valenta R, Duehene M, Pettenburger K, Sillaber C, Valent P, Bettelheim P, et al. Identification of profilin as a novel pollen allergen: IgE autoreactivity in sensitized individuals. Science 1991;253:557-60.
6. 2+. EMBO J 1994;13:3481-6.
7. 7. Twardosz A, Hayek B, Seiberler S, Vangelista L, Elfman L, Grönlund H, et al. Molecular characterization, expression in Escherichia coli and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem Biophys Res Commun 1997;239:197-204.
8. 8. Engel E, Richter K, Obermeyer G, Briza P, Kungl AJ, Simon B, et al. Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J Biol Chem 1997;272:28630-7.
9. 9. Elfman L, Svensson M, Lidholm J, Pauli G, Valenta R. Different profiles in specific IgE to rBet v 1 and rBet v 2 in patients allergic to birch pollen from six countries. Int Arch Allergy Immunol 1997;113:249-51.
10. 10. Jarolim E, Rumpold H, Endler AT, Ebner H, Breitenbach M, Scheiner O, et al. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 1989;44:385-95.
11. 11. Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, Hirschwehr R, et al. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 1991;88:889-94.
12. 12. Niederberger V, Pauli G, Grönlund H, Fröschl R, Rumpold H, Kraft D, et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998;102:579-91.
13. 13. Ebner C, Hirschwehr R, Bauer L, Breiteneder H, Valenta R, Ebner H, et al. Idenlificalion of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995;95:962-9.
14. 14. Valenta R. Sperr WR, Ferreira F, Valent P, Sillaber C, Tejkl M, et al. Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens. J Allergy Clin Immunol 1993;91:88-97.
15. 15. Ebner C, Ferreira F, Szephalusi Z, Jilek A, Valenta R, Parronchi P, et al. Identification of multiple T-cell epitopes on Bet v 1, the major birch pollen allergen using specific T-cell clones and overlapping peptides. J Immunol 1993:2150:1047-54.
16. 16. Ferreira F, Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K, Ebner C, Sommergruber W, et al. Purification and characterization of recombinant Bet v 1, the major birch pollen allergen. J Biol Chem 1993;268:19574-80.
17. 17. Menz G, Dolecek C, Schönheit-Kenn U, Ferreira F, Moser M, Schneider T, et al. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v 1, the major birch pollen allergen. Clin Exp Allergy 1996;26:50-60.
18. 18. Pauli G, Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, et al. Skin testing with recombinant allergens rBel v 1 and rBet v 2: diagnostic value for birch pollen and associated allergies. J Allergy Clin Immunol 1996;97:1100-9.
19. 19. Gajhede M, Osmark P, Poulsen FM. Ipsen H, Larsen JN, van Nerven J, et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat Struct Biol 1996;3:1040-5.
20. 20. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al. Conversion of the major birch pollen allergen. Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673-81.
21. 21. Hoffmann-Sommergruber K, Susani M, Ferreira F, Jertschin P, Ahorn H, Steiner R, et al. High-level expression and purification of the major birch pollen allergen, Bet v 1. Protein Expr Purif 1997;9:33-9.
22. 22. Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, et al. Genetic engineering of recombinant hypoallergenic oligomers of the major pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy 1999:118:218-9.
23. 23. Vrtala S, Grote M, Duchêne M, van Ree R, Kraft D, Scheiner O, et al. Properties of tree and grass pollen allergens: reinvestigation of the link-age between solubility and allergenicity. Int Arch Allergy Immunol 1993;102:160-9.
24. 24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
25. 25. Towbin H, Staehelin T, Gordon T. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
26. 26. Valenta R, Vrtala S, Laffer S. Spitzauer S, Kraft D. Recombinant allergens. Allergy 1998;53:552-61.
27. 27. Bousquet J, Lockey R, Malling HJ, World Health Organizaion. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper. J Allergy Clin Immunol 1998;102:558-62.
28. 28. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996;8:1937-45.
29. 29. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, et al. Successful immunotherapy with T-cell epitope peptides of the bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-54.
30. 30. Fritsche R, Pahud JJ, Pecquet S, Pfeifer A. Induction of systemic immunological tolerance to β-lactoglobulin by oral administration of a whey protein hydrolysate. J Allergy Clin Immunol 1997;100:266-73.
31. 31. Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982;70:248-60.
32. 32. Eriksson NE. Allergy to pollen from different deciduous trees in Sweden: an investigation with skin tests and the radioallergosorbent test (RAST) in springtime hay fever patients. Allergy 1978;33:299-309.
33. 33. Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-9.
34. 34. Kolbe L, Heusser C, Kolsch E. Antigen dose dependent regulation of B epsilon-memory cell expression. Int Arch Allergy Appl Immunol 1991;95:202-6.
35. 35. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28:914-25.
36. 36. Vrtala S, Ball T, Spitzauer S, Pandjaitan B, Suphioglu C, Knox B, et al. Immunization with purified natural and recombinant allergens induces mouse IgG 1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998;160:6137-44.